Inhibition of the kynurenine-NAD+ pathway leads to energy failure and exacerbates apoptosis in pneumococcal meningitis

Journal of Neuropathology and Experimental Neurology

Volumn 69, Issue 11, 2010, Pages 1096-1104

  Bellac, Caroline L ^a   Coimbra, Roney S ^a   Christen, Stephan ^a   Leib, Stephen L ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Apoptosis; Energy failure; Hippocampus; Kynurenine; Meningitis; Pharmacological inhibition; Streptococcus pneumoniae

Indexed keywords

2 METHOXYBENZOYLALANINE; 3 HYDROXYKYNURENINE; CEFTRIAXONE; HYDROLASE INHIBITOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; KYNURENINASE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXYGENASE INHIBITOR; RO 618048; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; APOPTOSIS; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG INHIBITION; ENZYME INHIBITION; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; METABOLITE; NONHUMAN; PATHOGENESIS; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENERGY METABOLISM; HIPPOCAMPUS; KYNURENINE; MENINGITIS, PNEUMOCOCCAL; MYELIN BASIC PROTEINS; NAD; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SULFONAMIDES; THIAZOLES;

EID: 78049341859     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181f7e7e9     Document Type: Article

References (55)

1. Grandgirard D, Leib SL. Strategies to prevent neuronal damage in paediatric bacterial meningitis. Curr Opin Pediatr 2006;18:112-18
2. Weisfelt M, van De Beek D, Spanjaard L, et al. Clinical features, complications, and outcome in adults with pneumococcal meningitis: A prospective case series. Lancet Neurol 2006;5:123-49
3. Free SL, Li LM, Fish DR, et al. Bilateral hippocampal volume loss in patients with a history of encephalitis or meningitis. Epilepsia 1996;37: 400-5
4. Hoogman M, van De Beek D, Weisfelt M, et al. Cognitive outcome in adults after bacterial meningitis. J Neurol Neurosurg Psychiatry 2007;78: 1092-96
5. Leib SL, Heimgartner C, Bifrare YD, et al. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res 2003;54:353-57
6. Loeffler JM, Ringer R, Hablutzel M, et al. The free radical scavenger alpha-phenyl-tert-butyl nitrone aggravates hippocampal apoptosis and learning deficits in experimental pneumococcal meningitis. J Infect Dis 2001;183:247-52
7. Nau R, Soto A, Brück W. Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J Neuropathol Exp Neurol 1999;58:265-74
8. Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002;2:721-36
9. Mitchell L, Smith SH, Braun JS, et al. Dual phases of apoptosis in pneumococcal meningitis. J Infect Dis 2004;190:2039-46
10. Zweigner J, Jackowski S, Smith SH, et al. Bacterial inhibition of phos-phatidylcholine synthesis triggers apoptosis in the brain. J Exp Med 2004;200:99-106
11. Bellac CL, Coimbra RS, Christen S, et al. Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury. Neurobiol Dis 2006;24:395-402
12. Guidetti P, Bates GP, Graham RK, et al. Elevated brain 3-hydroxy-kynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 2006;23:190-97
13. Guillemin GJ, Brew BJ, Noonan CE, et al. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 2005;31:395-404
14. Sanni LA, Thomas SR, Tattam BN, et al. Dramatic changes in oxida-tive tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. Am J Pathol 1998;152: 611-19
15. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004;4:12-17
16. Stone TW. Kynurenines in the CNS: From endogenous obscurity to therapeutic importance. Prog Neurobiol 2001;64:185-218
17. Stone TW, Mackay GM, Forrest CM, et al. Tryptophan metabolites and brain disorders. Clin Chem Lab Med 2003;41:852-59
18. Miu J, Ball HJ, Mellor AL, et al. Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria. Int J Parasitol 2009;39:363-70
19. Rodgers J, Stone TW, Barrett MP, et al. Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis. Brain 2009;132:1259-67
20. Grant RS, Passey R, Matanovic G, et al. Evidence for increased De novo synthesis of NAD in immune-activated RAW264.7 macrophages: A self-protective mechanism? Arch Biochem Biophys 1999;372:1-7
21. Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 1997;57: 1835-40 (Pubitemid 27209706)
22. Leist M, Single B, Castoldi AF, et al. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis. J Exp Med 1997;185:1481-86
23. Bifrare YD, Gianinazzi C, Imboden H, et al. Bacterial meningitis causes two distinct forms of cellular damage in the hippocampal dentate gyrus in infant rats. Hippocampus 2003;13:481-88
24. Leib SL, Kim YS, Black SM, et al. Inducible nitric oxide synthase and the effect of aminoguanidine in experimental neonatal meningitis. J Infect Dis 1998;177:692-700
25. Gianinazzi C, Grandgirard D, Imboden H, et al. Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis. Acta Neuropathol 2003;105:499-507
26. Pfister LA, Tureen JH, Shaw S, et al. Endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis. Ann Neurol 2000;47:329-35
27. Ghielmetti M, Ren H, Leib SL, et al. Impaired cortical energy metabolism but not major antioxidant defenses in experimental bacterial meningitis. Brain Res 2003;976:139-48
28. Klaidman LK, Leung AC, Adams JD Jr. High-performance liquid chro-matography analysis of oxidized and reduced pyridine dinucleotides in specific brain regions. Anal Biochem 1995;228:312-17
29. Rover S, Cesura AM, Huguenin P, et al. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 1997;40: 4378-85
30. Chiarugi A, Carpenedo R, Molina MT, et al. Comparison of the neu-rochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J Neurochem 1995;65: 1176-83
31. Guidetti P, Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 1999;11: 3857-63
32. Okuda S, Nishiyama N, Saito H, et al. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 1998;70: 299-307
33. Cozzi A, Carpenedo R, Moroni F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: Studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J Cereb Blood Flow Metab 1999;19:771-77
34. Grant RS, Naif H, Espinosa M, et al. IDO induction in IFN-gamma activated astroglia: A role in improving cell viability during oxidative stress. Redox Rep 2000;5:101-4
35. Clark RS, Vagni VA, Nathaniel PD, et al. Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. J Neurotrauma 2007;24:1399-405
36. Koedel U, Winkler F, Angele B, et al. Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase. J Cereb Blood Flow Metab 2002;22:39-49
37. Barr TL, Conley YP. Poly(ADP-ribose) polymerase-1 and its clinical applications in brain injury. J Neurosci Nurs 2007;39:278-84
38. Lenzser G, Kis B, Snipes JA, et al. Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats. J Cereb Blood Flow Metab 2007;27:1318-26
39. Moroni F. Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage. Curr Opin Pharmacol 2008;8:96-103
40. Ying W. NAD+ and NADH in neuronal death. J Neuroimmune Pharmacol 2007;2:270-75
41. Ying W. NAD+ and NADH in brain functions, brain diseases and brain aging. Front Biosci 2007;12:1863-88
42. Guidetti P, Eastman CL, Schwarcz R. Metabolism of [5-3H]kynurenine in the rat brain in vivo: Evidence for the existence of a functional kynurenine pathway. J Neurochem 1995;65:2621-32
43. Amori L, Guidetti P, Pellicciari R, et al. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neu-rochem 2009;109:316-25
44. Tsuchiyama R, Sozen T, Manaenko A, et al. The effects of nicotinamide adenine dinucleotide on intracerebral hemorrhage-induced brain injury in mice. Neurol Res 2009;31:179-82
45. Holland MA, Tan AA, Smith DC, et al. Nicotinamide treatment provides acute neuroprotection and GFAP regulation following fluid percussion injury. J Neurotrauma 2008;25:140-52
46. Lopes C, Pereira EF, Wu HQ, et al. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J Pharmacol Exp Ther 2007;322: 48-58
47. Obrenovitch TP, Urenjak J. In vivo assessment of kynurenate neuro-protective potency and quinolinate excitotoxicity. Amino Acids 2000;19: 299-309
48. Urenjak J, Obrenovitch TP. Neuroprotective potency of kynurenic acid against excitotoxicity. Neuroreport 2000;11:1341-44
49. Vesce S, Rossi D, Brambilla L, et al. Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. Int Rev Neurobiol 2007;82:57-71
50. Leib SL, Kim YS, Ferriero DM, et al. Neuroprotective effect of excitatory amino acid antagonist kynurenic acid in experimental bacterial meningitis. J Infect Dis 1996;173:166-71
51. Biegon A, Fry PA, Paden CM, et al. Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits. Proc Natl Acad Sci \USA 2004;101:5117-22
52. Potter MC, Elmer GI, Bergeron R, et al. Reduction of endogenous kyn-urenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 2010;35: 1734-42
53. Ikonomidou C, Stefovska V, Turski L. Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci \USA 2000;97: 12885-90
54. Pohl D, Bittigau P, Ishimaru MJ, et al. N-methyl-D-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain. Proc Natl Acad Sci \USA 1999;96:2508-13
55. Sellner J, Ringer R, Baumann P, et al. Effect of the NMDA-receptor antagonist dextromethorphan in infant rat pneumococcal meningitis. Curr Drug Metab 2008;9:83-88